The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
High PD-L1 expression among patients with ALK rearranged non–small cell lung cancer and response to first line ALK tyrosine kinase inhibitors.
 
Yunan Nie
No Relationships to Disclose
 
Alyse Staley
No Relationships to Disclose
 
Trista Hinz
No Relationships to Disclose
 
Dan Merrick
No Relationships to Disclose
 
Michael Yang
No Relationships to Disclose
 
Erin L. Schenk
Honoraria - Horizon CME; Horizon CME; Ideology Health; Janssen; MECC Global Meetings; MJH Life Sciences; OncLive; OncLive; Regeneron; Takeda
Consulting or Advisory Role - Actinium Pharmaceuticals; AstraZeneca; BioAtla; Bionest partners; ClearView Healthcare Partners; G1 Therapeutics; Guidepoint Global; Prescient Healthcare Group; Regeneron; Regeneron; The Scienomics Group
 
Paul A. Bunn
Leadership - Verastem
Honoraria - Ascentage Pharma; AstraZeneca; BMS; CStone Pharmaceuticals; Imedex; Lilly/ImClone; Merck; Viecure
Consulting or Advisory Role - Ascentage Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; CStone Pharmaceuticals; Genentech/Roche; Imedex; Imedex; Merck; viecure
Travel, Accommodations, Expenses - Verastem
 
David Ross Camidge
Honoraria - Abbvie; Amgen Astellas BioPharma; Anheart Therapeutics; Apollomics; AstraZeneca; BeiGene; BeiGene; bio-thera; Daiichi Sankyo; Dizal Pharma; Elevation Oncology; EMD Serono; Helsinn Therapeutics; Hengrui Pharmaceutical; Hummingbird; Janssen; Kestrel Labs; Lilly; Mersana; Mirati Therapeutics; nalo therapeutics; Nuvalent, Inc.; OnKure; Puma Biotechnology; Ribon Therapeutics; Roche; Sanofi; Seagen; takeda; Turning Point Therapeutics
Research Funding - Inivata (Inst)
 
Lynn Heasley
No Relationships to Disclose
 
Tejas Patil
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Daiichi Sankyo/Astra Zeneca; Elevation Oncology; Janssen; Jazz Pharmaceuticals; Mirati Therapeutics; Pfizer; Regeneron; Takeda; Turning Point Therapeutics
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Gilead Sciences (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Gilead Sciences; Takeda